MICHAEL BARZA, M.D.; STEPHEN G. PAUKER, M.D.
The availability of vidarabine for the therapy of suspected herpes simplex encephalitis presents a difficult decision for a physician as to whether to do brain biopsy, to treat blindly, or to withhold specific therapy in a patient. The choice is made more difficult because the physician must weigh four likelihoods simultaneously: namely, of the disease, of a life-threatening complication from biopsy, of a beneficial effect from vidarabine, and of a serious adverse effect from the drug. Using decision analysis, we have derived a series of threshold probabilities whereby the physician can select his own estimates of these likelihoods to arrive at a rational approach to management. When reasonable assessments are made of the risks of biopsy and of vidarabine therapy, brain biopsy is likely to be the optimal approach in the majority of patients suspected of having herpes simplex encephalitis.
BARZA M, PAUKER SG. The Decision to Biopsy, Treat, or Wait in Suspected Herpes Encephalitis. Ann Intern Med. ;92:641–649. doi: 10.7326/0003-4819-92-5-641
Download citation file:
© 2018
Published: Ann Intern Med. 1980;92(5):641-649.
DOI: 10.7326/0003-4819-92-5-641
Infectious Disease.
Results provided by: